Biology of Blood and Marrow Transplantation
Volume 13, Issue 6 , Pages 655-664 , June 2007

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation

  • Philippe Armand

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Haesook T. Kim

      Affiliations

    • Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Daniel J. DeAngelo

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Vincent T. Ho

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Corey S. Cutler

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Richard M. Stone

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Jerome Ritz

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Edwin P. Alyea

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Joseph H. Antin

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Robert J. Soiffer

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Robert Soiffer, MD, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115.

Received 22 November 2006 ,Accepted 22 January 2007.

  • Image Result

    Survival, relapse, and nonrelapse mortality for all de novo patients, stratified by cytogenetics according to new grouping scheme. (A) Overall survival, (B) disease-free survival, (C) cumulative incid

    Survival, relapse, and nonrelapse mortality for all de novo patients, stratified by cytogenetics according to new grouping scheme. (A) Overall survival, (B) disease-free survival, (C) cumulative incidence of relapse, (D) nonrelapse mortality.

  • Image Result
    Overall survival of patients with AML, stratified by cytogenetics according to new grouping scheme. (A) Patients with AML in CR1, (B) patients with AML beyond CR1.

    Overall survival of patients with AML, stratified by cytogenetics according to new grouping scheme. (A) Patients with AML in CR1, (B) patients with AML beyond CR1.

  • Image Result
    Survival of all patients with therapy-related disease, stratified by cytogenetics according to new grouping scheme. (A) Overall survival, (B) disease-free survival. Note that the favorable group inclu

    Survival of all patients with therapy-related disease, stratified by cytogenetics according to new grouping scheme. (A) Overall survival, (B) disease-free survival. Note that the favorable group included only 2 patients.

PII: S1083-8791(07)00139-5

doi: 10.1016/j.bbmt.2007.01.079

Biology of Blood and Marrow Transplantation
Volume 13, Issue 6 , Pages 655-664 , June 2007

Article Tools

* Image Usage & Resolution